Press release
Increasing Cardiovascular Diseases Drives Market Growth Driver: A Major Catalyst in the Evolution of the Hypercholesterolemia Market in 2025
Hypercholesterolemia
The increasing incidence of cardiovascular diseases is expected to drive the growth of the hypercholesterolemia market. Cardiovascular diseases (CVDs) include a range of disorders that affect the heart and blood vessels. The rise in cardiovascular diseases is attributed to unhealthy diets, physical inactivity, obesity, chronic stress, aging populations, and the prevalence of conditions such as hypertension and diabetes. Hypercholesterolemia treatment helps manage cardiovascular disease by lowering LDL cholesterol levels, reducing arterial plaque buildup, enhancing blood flow, and decreasing the risk of heart attacks, strokes, and other cardiovascular complications. For example, in October 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that approximately 805,000 people in the United States experience a heart attack annually, with 605,000 of these being first-time incidents and 200,000 involving individuals who have had a previous heart attack. Consequently, the rise in cardiovascular diseases is expected to drive the growth of the hypercholesterolemia market.
Get Your Hypercholesterolemia Market Report Here:
https://www.thebusinessresearchcompany.com/report/hypercholesterolemia-global-market-report
How will the growth rate of the hypercholesterolemia market shape industry trends by 2034?
The hypercholesterolemia market has experienced rapid expansion, growing from $16.30 billion in 2024 to $18.66 billion in 2025 at a CAGR of 14.5%. Growth has been driven by increased health campaigns, expanded R&D activities, a focus on preventive healthcare, and rising preventive health screenings and lifestyle modifications.
The hypercholesterolemia market is projected to witness rapid expansion over the next few years, reaching $31.70 billion by 2029, with a compound annual growth rate (CAGR) of 14.2%. The anticipated growth during this period is attributed to advancements in screening and diagnostics, supportive government health policies, increasing awareness of cholesterol risks, rising availability of over-the-counter (OTC) cholesterol-lowering medications, and the growing prevalence of risk factors. Key trends expected in this period include innovations in lipid profiling, advancements in nanotechnology for drug delivery, robotic-assisted surgical techniques, increased use of telemedicine platforms, and targeted lipoprotein therapies.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21207&type=smp
What trends are poised to drive the future success of the hypercholesterolemia market?
In the hypercholesterolemia market, companies are developing innovative triple-combination drugs to enhance treatment efficacy and improve patient compliance. These drugs combine three active ingredients into a single formulation, simplifying treatment regimens. For instance, in February 2025, Celltrion Pharm, Inc., a South Korea-based pharmaceutical company, launched Amrozet Tablet, a combination therapy for hypertension and hyperlipidemia. The medication combines amlodipine (a calcium channel blocker for hypertension), rosuvastatin (a statin for lowering cholesterol), and ezetimibe (a cholesterol absorption inhibitor). Available in various dosage combinations, Amrozet is indicated for hypertension, primary hypercholesterolemia, and to alleviate angina in patients with coronary artery disease, offering a convenient treatment option for patients with multiple conditions.
Which primary segments of the hypercholesterolemia market are driving growth and industry transformations?
The hypercholesterolemia market covered in this report is segmented -
1) By Disease Type: Genetic, Acquired
2) By Treatment: Statins, Bile Acid Resins, Niacin, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Other Treatments
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others Distribution Channel
5) By End User: Hospitals, Specialty Clinics, Home Healthcare, Others End Users
Subsegments:
1) By Genetic: Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
2) By Acquired: Primary Hypercholesterolemia, Secondary Hypercholesterolemia
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21207
Which geographical regions are pioneering growth in the hypercholesterolemia market?
North America was the largest region in the hypercholesterolemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hypercholesterolemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the influential players reshaping the hypercholesterolemia market landscape?
Major companies operating in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., Melinta Therapeutics Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21207&type=smp
What Is Covered In The Hypercholesterolemia Global Market Report?
•Market Size Forecast: Examine the hypercholesterolemia market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the hypercholesterolemia market for a structured understanding.
•Key Players Overview: Analyze major players in the hypercholesterolemia market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the hypercholesterolemia market.
•Segment Contributions: Evaluate how different segments drive overall growth in the hypercholesterolemia market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the hypercholesterolemia market.
•Industry Challenges: Identify potential risks and obstacles affecting the hypercholesterolemia market.
•Competitive Landscape: Review strategic developments in the hypercholesterolemia market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Increasing Cardiovascular Diseases Drives Market Growth Driver: A Major Catalyst in the Evolution of the Hypercholesterolemia Market in 2025 here
News-ID: 3936930 • Views: …
More Releases from The Business Research Company
Surgical Retractors Market Trends That Will Shape the Next Decade: Insights from …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Surgical Retractors Market Size By 2025?
The market size for surgical retractors has experienced notable growth over recent years. The market, which was valued at $2.45 billion in 2024, is projected to increase to $2.57 billion in 2025, following a compound annual growth rate (CAGR)…
Transformative Trends Impacting the Cataract Surgery Devices And Equipment Marke …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Cataract Surgery Devices And Equipment Market Size By 2025?
The market size for cataract surgery devices and equipment has shown a consistent growth trend in recent years. It is projected to increase from $13.97 billion in 2024 to $14.52 billion in 2025, exhibiting a compound…
Rising Demand For Minimally Invasive Surgery Drives Growth In Robotic Surgery De …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Robotic Surgery Devices Market Size Growth Forecast: What to Expect by 2025?
The market for robotic surgery devices has experienced a swift expansion in the past years. Its size is projected to increase from $7.84 billion in 2024 to $8.81 billion in 2025, with a compound annual growth rate…
Steady Expansion Forecast for Orthopedic Devices Market, Projected to Reach $61. …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Orthopedic Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of orthopedic devices has witnessed substantial growth in the past few years. The market, which stood at $47.78 billion in 2024, is projected to increase to $50.26 billion in 2025, reflecting a…
More Releases for Hypercholesterolemia
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Hypercholesterolemia Treatment Market Reviews Analysis Report 2024
Hypercholesterolemia Treatment Market to reach over USD 36.37 billion by the year 2031 - Exclusive Report by InsightAce Analytic
According to a new report by InsightAce Analytic, the "Hypercholesterolemia Treatment Market" in terms of revenue was estimated to be worth $27.9 billion in 2023 and is poised to reach $36.37 billion by 2031, growing at a CAGR of 3.43% from 2024 to 2031.
Get a free Sample copy of the…
Hypercholesterolemia Treatment Market: Transforming Lives: Impact of Hypercholes …
Newark, New Castle, USA: The "Hypercholesterolemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypercholesterolemia Treatment Market: https://www.growthplusreports.com/report/hypercholesterolemia-treatment-market/8571
This latest report researches the industry structure, sales, revenue,…
Hypercholesterolemia Treatment Market Insights, Forecast to 2031
The report extensively examines the global Hypercholesterolemia Treatment market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hypercholesterolemia Treatment . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Hypercholesterolemia Market Global Analysis & 2023 Forecast Report
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
